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Affection de l’appareil locomoteur (I) / Revue d’E´pide´miologie et de Sante´ Publique 55S (2012) e48–e53e52contractures. Here, we present two case reports suggesting a definite interest in
this domain.
Methods.– We reviewed patients who received BTI (2006–2011) for post-
traumatic contractures of the upper limb. They were assessed for passive and
active range of movement, pain (visual analogic scale) and passive and active
functions.
Case reports.– The first patient suffered from severe and painful post-traumatic
contractures of elbow and wrist flexors, following elbow dislocation, which
severely limited joint extension and use of the hand. Oral treatment and
physiotherapy had a very limited effect. Repeated BTI were performed in
contractured and painful muscles, with limited doses (100U Botox#), each 2–3
months. In the 4–5 days following each injection, contracture and pain were
reduced and this favoured active function of the antagonist muscles. Recovery was
complete after four injection sessions, with fair satisfaction level. The second
patient had been the victim of a traumatic injury of the upper extremity, with
compartment syndrome. She suffered from severe multifocal painful contractures,
impairing daily living, with loss of usage of the limb. Oral treatments and physical
therapy had a modest effect. Iterative BTI were performed every four months
(200U Botox#) for four years, with a partial, recurrent and constant gain on pain,
active motricity, use of the limb, and level of satisfaction
Conclusion.– Following arthroplasty, BTI has yet shown definite effect on
painful contractures of the hip and knee. Here, we present the first reports of
such a symptomatic and functional effect on severe post-traumatic contractures.
Botulinum toxin injections must be considered as a useful treatment for post-
traumatic disabling contractures.
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Introduction.– Etiologies of exertional leg pain are numerous and may be
associated. This diversity requires a precise diagnostic break-up, and makes its
therapeutic management sometimes complex. How should some abnormalities
(supernumerary muscles, functional popliteal arteries entrapment) be handled
when their imputability in pain is uncertain? Botulinum toxin type A (BTX-A)
has been successfully used for several years in some lesions of the locomotor
apparatus. Our objective is to demonstrate its diagnostic and therapeutic interest
in the chronic compartment syndrome (CCS), functional popliteal artery
entrapment syndrome and the accessory soleus muscle.Observation.– We are
presenting a few studies or case series which are in the process of being analysed
or published. The first open and prospective study demonstrates the diagnostic
and therapeutic interest of BTX-A in 31 patients with antero-external CCS of
the leg of a mean duration of 31 months. Pain disappeared in 97% of cases. A
moderate muscular deficiency is nearly constant and disappears between 1 and 5
months in 94% of cases, preventing only exceptionally an early resumption of
running. Intramuscular pressures, three months after BTX-A, had normalized.
Eight patients presented a recurrence of pain between 6 and 30 months.
In three patients with painful accessory soleus muscle treated by BTX-A
injection within the muscle by stimulodetection, pain had disappeared. Two
patients relapsed at distance.
Five patients presenting with a functional trapped popliteal artery without
anatomical lesion were treated by BTX-A injection. The results are in the
process of analysis. A first patient was able to resume sport, as pain had
disappeared and the echographic dynamic abnormalities had normalized.Dis-
cussion.– The precise use of BTX-A is a useful adjuvant in the diagnostic break-
up of exertional leg pain, in addition to the absolutely essential complementary
tests. It allows precising the imputability of anatomical or functional
abnormalities in the origin of pain. BTX-A has its own therapeutic actionallowing a prolonged amendment of some types of pain. In case of recurrence, it
is an excellent pre-surgical test in non-responding pain with uncertain surgical
results.
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Introduction.– CRPS remains a phenomenon not clearly understood
physiologically. Three phases follow one another: hot, cold and retractile. A
symptomatic element of dystonia may appear from the cold phase,
characterized by tonic muscle contractions and abnormal postures.
Observation.– A 42 year old woman presents with a epitrochlea fracture of the
left humerus further complicated by ulnar nerve compression which was treated
by arthroscopic surgery. Two years later, with no obvious trigger, the patient
develops pain and swelling of the left arm, and a progressive stiffness of the
hand of attributed to (CRPS). Clinical examination of passive range of motion
revealed the following limitations: shoulder abduction of 308, flexion at 408,
elbow pronation of 608, supination to –458, writs extension of –608, radial
rotation at –208 and pulpo-palmar distance of II to V fingers at 0 mm. The
patient was treated with marcaine for regional local nerve blocks followed by
intensive rehabilitation, without results. Three years later, the patient was
referred to us for further treatment of her dystonia. We used botulinum toxin to
inject the trapezius, teres major, pectoralis major, pronator teres, flexor carpi
radialis, superficial and deep common flexors of the second to fifth fingers. We
used alcohol nerve blocks administered to the palmar muscles, common flexors,
and flexor pollicis longus 15 days later resulting in a clear measurable functional
improvements with shoulder abduction of 808, shoulder flexion of 1508, elbow
pronation 908 and supination to 808, wrist extension at 308, radial rotation of 08,
and the pulpo-palmar distances of 80 mm, 50 mm, 60 mm, 70 mm for second,
third, fourth, and fifth fingers, respectively.
Discussion.– The literature on CRPS dystonia is very scarce, the use of
botulinum toxin as well as intensive active and passive rehabilitation in
conjunction with psychotherapy can be an effective therapeutic combination.
Further reading
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Introduction.– Botulinum toxin (BT) can be used in the treatment of neck and
upper limb pain and in the management of low back pain with or without
sciatica. Its use and justification in these indications are based on the myofascial
pain concept according to Travell, which would be a malfunction of the motor
endplate with excessive release of acetylcholine.
Affection de l’appareil locomoteur (I) / Revue d’E´pide´miologie et de Sante´ Publique 55S (2012) e48–e53 e53Material and method.– We describe the use of TB in the treatment of cervico-
thoracic and lumbar myofascial syndrome (MFS): systematic review of the
literature.
Results.– For the neck, the cervico-thoracic SMF concern the upper trapezius,
supraspinatus, rhomboids, angular, and cervical paraspinal muscles [1]. After
BT injection, prospective studies show an improvement in pain and quality of
life for 3 months. Randomized controlled trials (RCT) found at 1 and 3 months
analgesics and functional results with BT equivalent to other products (saline,
corticosteroids) and dry needle therapy. Two RCTs show a greater analgesic and
functional effect 1 and 2 months after BT injections compared to saline solution.
For upper limb pain, one RCT (MFS of the scalene muscle), shows after BT
injection an analgesic gain at two months superior to corticosteroid injections.
For low back pain, the MFS concern iliopsoas, erector spinae and rectus of the
abdomen. Foster et al. [2] show that after injection of TB in the erector spinae
muscles, pain relief and functional gain to 1 and 2 months are greater than the
saline injection. Similar results were found compared to traditional treatment by
acupuncture.
Conclusions.– The use of BT in the treatment of neck pain and low back pain is
an interesting alternative therapeutic in axial MFS. Its superiority compared to
other treatments remains to be demonstrated.
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Purpose.– Rehabilitation of orthopaedic articular stiffness represents a major
therapeutic challenge. In rebellious cases, injection of botulinic toxin in bi-
articular muscles could represent an interesting adjunction to the usual
therapies.
Observations.–
– A 29-years-old female patient hospitalised after her fourth knee arthrolysis
following an anterior cruciate ligament reconstruction. At admission, the ROM
was F/E 908-0-58. Rapidly a 258 stiff knee flexion appears with important
difficulties while walking. The electro-neuromyography shows a hyperactivity
of hamstrings semi-membranous and short head of the femoral biceps muscles.
Injections of 100U of botulinic toxin in femoral biceps, 50U in the others
hamstrings and gastrocnemius muscles were done. After 3 weeks the stiff knee
flexion progressively reduces (F/E 1258-5-08), pain reduces by 30% and
walking improves (see videos). At 3 and 6 months, injections were repeated for
a persistent muscular hyperactivity. At 1 year, the pattern of walking is back to
normal. The patient has fully returned to work and started adapted sport
activities.
– A 34 years old patient that had surgery for a radial head dislocation and
fracture. Osteosynthesis material was taken off 13months followed by a
secondary stiffening resisting ambulatory treatment. At entry, the ROM was
F/E 1308-608-0 with a stiff stop in extension. Prono/supp 808-0-608. On theEMG: biceps muscular hyperactivation. Injection of 25U of botulinic toxin in
biceps short head followed by intensive physiotherapy and occupational therapy
for 5 weeks. Decrease in biceps hypertonia 7 days after the injection. ROM at
discharge F/E 1358-128-0, P/S 808-0-608. Progressive return to work as a
heating engineer achieved. At 3 months: F/E: 1308-258-0, P/S: 808-0-608.
Discussion.– Most often used in treatment of spasticity, botulin toxin could in
some cases allow to break a vicious circle. The neuromouscular blockade allows
a decrease in muscular tonus and facilitates rehabilitation. The toxin transported
through the axons to the central nervous system and the adjacent neurones also
show an analgesic effect through the modulation of some neurotransmitters’
secretion such as the substance P, CGRP and glutamate.
Further reading
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Objective.– The piriformis muscle syndrome (PMS) arises a problem as
diagnostic because there are not clinical and paraclinical pathognomonic signs,
as therapeutic. The chronic PMS can be treated by muscular injection of
botulinum toxin (BTA). The objective is to assess the efficiency and the interest
of BTA.
Methods and patients.– Retrospective study of 46 patients treated by piriformis
injection of BTA guided by CT. Clinical, electrological and imaging diagnosis
rules out the spine and pelvic causes of buttock pain and/or sciatalgia. Pain
assessment by the patient: decrease < or  50% of the pre-therapeutic pain.
Results.– Sixteen patients are examined at 4 months: 62,5% of good results
(pain decrease  50%). Second BTA injection in 12 patients: 63% of good
results but during only 1 month. Third BTA injection in three patients: 100% of
good results during only 1 month. Phone assessment of 14 patients with initial
good results: Five patients think to have a partial benefit continuing at mean 30
months. Correlation don’t exist between results and age, the time elapsed since
the beginning of the PMS (mean 33  44 months), the low back pain, the
location of the pain, the electrological modifications of the H reflex.
Discussion.– Four published studies find a statistically significant efficiency of
the BTA between 2 and 4 months. In our study these good results don’t last more
long time. The BTA injection repetition don’t give a cumulative effect and the
efficiency even decreases. So, the therapeutic interest is limited. On the other
hand the BTA transitory efficiency at short-term could be used to confirm the
diagnosis of PMS because BTA has its principal action in muscle without
diffusion, contrary the corticoids.
Conclusion.– The BTA injection into the piriformis muscle for the chronic or
resistant PMS is becoming for us a certain diagnosis test associated to clinical
and paraclinical signs for the aim to better select the patients to a surgical
treatment. Nevertheless, the validity of this strategy must be confirmed by a
prospective study.
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